Biocon Biologics companions with The Worldwide Diabetes Federation


For affordable access to insulin for diabetes care

Biocon Biologics, a subsidiary of Biocon, has partnered with the International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support the initiative and activities of the IDF core mission. This important partnership with IDF coincides with the centenary of the discovery of insulin and continues Biocon Biologics’ mission to provide affordable access to insulin to people with diabetes worldwide.

Nearly a century after the discovery of insulin, millions of people with diabetes are denied regular and affordable access to this life-saving therapy. Not only do people with diabetes have difficulty accessing insulin in emerging countries, people in developed countries like the United States also have difficulty affording insulin therapy. As a credible global insulin player who has delivered more than 2 billion doses of human insulin to date, Biocon Biologics has worked with key stakeholders on various global forums to find ways to improve affordable access to insulin and ensure therapy reaches them who you need them most.

Powered by Capital Market – Live News

(This story was not edited by Business Standard staff and is automatically generated from a syndicated feed.)

Dear Reader,

Business Standard has always endeavored to provide updated information and commentary on developments that are of interest to you and have far-reaching political and economic implications for the country and the world. Your encouragement and constant feedback to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these troubled times resulting from Covid-19, we continue to strive to keep you updated with credible news, authoritative views, and concise comments on relevant topics.
However, we have a request.

As we struggle against the economic impact of the pandemic, we need your support even more so that we can continue to provide you with higher quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. A larger subscription to our online content can only help us achieve our goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support of quality journalism and Subscribe to Business Standard.

Digital editor